IGM Biosciences Company Overview
About IGM Biosciences
IGM Biosciences (NASDAQ:IGMS) is a biotechnology firm deeply engaged in researching and developing therapies that harness the power of the immune system to treat cancer and other serious diseases. At the heart of its operation, IGM Biosciences focuses on creating and advancing a broad portfolio of engineered IgM antibodies designed to target and eliminate cancer cells with unprecedented precision and efficiency. With a firm commitment to improving patient outcomes, the company is spearheading several projects through various stages of preclinical and clinical development. Its objectives extend to rapidly translating groundbreaking scientific discoveries into novel therapeutic options that can address unmet medical needs and significantly improve the lives of patients around the world.
Snapshot
Operations
Produtos e/ou serviços de IGM Biosciences
- IGM-2323, a CD20 x CD3 bispecific antibody in Phase 1/2 trials for Non-Hodgkin's Lymphoma.
- IGM-8444, a DR5 agonist antibody in trials for solid and hematologic malignancies.
- IGM-7354, an IL-15 immunostimulatory bispecific antibody designed for the treatment of cancer.
- Preclinical bispecific antibodies targeting PD-1 and LAG-3 for advanced solid tumors.
- IGM-2644, an anti-CD38 x CD3 bispecific antibody for multiple myeloma.
- Technology platforms for developing engineered IgM and IgA antibodies for enhanced therapeutic effects.
equipe executiva do IGM Biosciences
- Ms. Mary Beth Harler M.D.CEO & Director
- Mr. Paul C. Graffagnino J.D.Senior Vice President of Legal Affairs